Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung cancer: a multicenter retrospective study

BACKGROUND: Brain metastases (BMs) develop in 20–65% of non-small cell lung cancer (NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular endothelial growth factor receptor 2, is safe and significantly prolongs th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jia, Bi, Jianping, Tuo, Xiulin, Pi, Guoliang, Li, Ying, Li, Yanping, Zeng, Fanyu, Gong, Hongyun, Hu, Desheng, Han, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902115/
https://www.ncbi.nlm.nih.gov/pubmed/35280489
http://dx.doi.org/10.21037/jtd-22-96

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902115/
https://www.ncbi.nlm.nih.gov/pubmed/35280489
http://dx.doi.org/10.21037/jtd-22-96

Ejemplares similares